151 related articles for article (PubMed ID: 16115232)
1. Serous borderline tumours of the ovary.
Kurman RJ; Seidman JD; Shih IM
Histopathology; 2005 Sep; 47(3):310-5. PubMed ID: 16115232
[TBL] [Abstract][Full Text] [Related]
2. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
Russell SE; McCluggage WG
J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
[TBL] [Abstract][Full Text] [Related]
3. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
4. The pathology of and controversial aspects of ovarian borderline tumours.
McCluggage WG
Curr Opin Oncol; 2010 Sep; 22(5):462-72. PubMed ID: 20531187
[TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.
Shih IeM; Kurman RJ
Clin Cancer Res; 2005 Oct; 11(20):7273-9. PubMed ID: 16243797
[TBL] [Abstract][Full Text] [Related]
7. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
8. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
Kane SV; Bharadwaj R; Tongaonkar HB
Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
[TBL] [Abstract][Full Text] [Related]
9. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A
Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
[TBL] [Abstract][Full Text] [Related]
11. Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants.
Sieben NL; Roemen GM; Oosting J; Fleuren GJ; van Engeland M; Prat J
J Pathol; 2006 Dec; 210(4):405-11. PubMed ID: 17096315
[TBL] [Abstract][Full Text] [Related]
12. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
[TBL] [Abstract][Full Text] [Related]
13. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
14. Serous tumours of low malignant potential (serous borderline tumours): moving toward détente.
Longacre TA; Kempson RL; Hendrickson MR
Histopathology; 2005 Sep; 47(3):315-8. PubMed ID: 16115233
[No Abstract] [Full Text] [Related]
15. Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
Ueda M; Toji E; Noda S
Int J Gynecol Cancer; 2007; 17(4):794-7. PubMed ID: 17309670
[TBL] [Abstract][Full Text] [Related]
16. Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM; Anglesio MS; Sharma R; Gilks CB; Melnyk N; Chiew YE; deFazio A; ; Longacre TA; Huntsman DG; Gorringe KL; Campbell IG
Clin Cancer Res; 2011 Dec; 17(23):7273-82. PubMed ID: 21976534
[TBL] [Abstract][Full Text] [Related]
17. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
[TBL] [Abstract][Full Text] [Related]
18. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.
Bell DA; Longacre TA; Prat J; Kohn EC; Soslow RA; Ellenson LH; Malpica A; Stoler MH; Kurman RJ
Hum Pathol; 2004 Aug; 35(8):934-48. PubMed ID: 15297961
[TBL] [Abstract][Full Text] [Related]
19. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
[TBL] [Abstract][Full Text] [Related]
20. Diverse tumorigenic pathways in ovarian serous carcinoma.
Singer G; Kurman RJ; Chang HW; Cho SK; Shih IeM
Am J Pathol; 2002 Apr; 160(4):1223-8. PubMed ID: 11943707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
